TY - JOUR
T1 - Oligonucleotide aptamers
T2 - New tools for targeted cancer therapy
AU - Sun, Hongguang
AU - Zhu, Xun
AU - Lu, Patrick Y.
AU - Rosato, Roberto R.
AU - Tan, Wen
AU - Zu, Youli
N1 - Funding Information:
This project was supported in part by NIH grants R01CA151955 and R33CA173382 to Y.Z.
PY - 2014/8/5
Y1 - 2014/8/5
N2 - Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed "chemical antibodies." In contrast to protein antibodies, aptamers offer unique chemical and biological characteristics based on their oligonucleotide properties. Hence, they are more suitable for the development of novel clinical applications. Aptamer technology has been widely investigated in various biomedical fields for biomarker discovery, in vitro diagnosis, in vivo imaging, and targeted therapy. This review will discuss the potential applications of aptamer technology as a new tool for targeted cancer therapy with emphasis on the development of aptamers that are able to specifically target cell surface biomarkers. Additionally, we will describe several approaches for the use of aptamers in targeted therapeutics, including aptamer-drug conjugation, aptamer-nanoparticle conjugation, aptamer-mediated targeted gene therapy, aptamer-mediated immunotherapy, and aptamer-mediated biotherapy.
AB - Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed "chemical antibodies." In contrast to protein antibodies, aptamers offer unique chemical and biological characteristics based on their oligonucleotide properties. Hence, they are more suitable for the development of novel clinical applications. Aptamer technology has been widely investigated in various biomedical fields for biomarker discovery, in vitro diagnosis, in vivo imaging, and targeted therapy. This review will discuss the potential applications of aptamer technology as a new tool for targeted cancer therapy with emphasis on the development of aptamers that are able to specifically target cell surface biomarkers. Additionally, we will describe several approaches for the use of aptamers in targeted therapeutics, including aptamer-drug conjugation, aptamer-nanoparticle conjugation, aptamer-mediated targeted gene therapy, aptamer-mediated immunotherapy, and aptamer-mediated biotherapy.
KW - cell surface biomarker
KW - nanomedicine
KW - oligonucleotide aptamer
KW - SELEX
KW - targeted cancer therapy
UR - http://www.scopus.com/inward/record.url?scp=84907312881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907312881&partnerID=8YFLogxK
U2 - 10.1038/mtna.2014.32
DO - 10.1038/mtna.2014.32
M3 - Review article
AN - SCOPUS:84907312881
SN - 2162-2531
VL - 3
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
M1 - e182
ER -